FAST III Study Confirms CAAS vFFR's Non-Inferiority to Invasive Wire-Based FFR Techniques

The FAST III Study: A Milestone in Cardiovascular Treatment

The FAST III trial has recently garnered attention in the medical community for its groundbreaking results comparing the CAAS vFFR (vessel Fractional Flow Reserve) to the traditional wire-based FFR methods. Initiated five years ago, this major study set out to determine if angiography-based CAAS vFFR could deliver equivalent therapeutic outcomes as the established wire-dependent techniques for coronary revascularization.

The Significance of the Study

Presented during the “Late-Breaking Clinical Trials” session at the American College of Cardiology (ACC) 2026 congress and published in the New England Journal of Medicine, the findings affirm the non-inferiority of CAAS vFFR. This outcome is highly significant, validating CAAS vFFR as a reliable alternative for guiding revascularization procedures, particularly in patients with intermediate coronary stenoses.

The study was supported by a partnership between Pie Medical Imaging, a leader in heart imaging solutions, and Siemens Healthineers, among others. With the success of the FAST III trial, there are immense implications for cost-effective and less invasive testing methods, creating better accessibility for patients requiring coronary evaluations.

Trial Methodology

In this multicenter, open-label study, researchers compared two approaches to coronary revascularization involving 2,235 patients with intermediate coronary lesions determined by visual assessments. The patients were randomized into two groups: those receiving vFFR-guided treatment and those receiving traditional FFR techniques. The principal endpoint evaluated a composite of all-cause mortality, myocardial infarction, or revascularization that occurred within one year following randomization.

The meticulous efforts led by the principal investigator Dr. Joost Daemen, a cardiologist from Erasmus University Medical Center in Rotterdam, facilitated the successful completion of the trial's primary endpoint. The resulting Major Adverse Cardiac Events (MACE) rates for both groups demonstrated identical risks, showcasing the efficacy of the vFFR technique.

Expert Opinions and Future Implications

Dr. Joost Daemen remarked, “The outcomes of FAST III confirm the safety and feasibility of employing vFFR online as a straightforward, minimal-invasive tool for directing revascularization in patients with intermediate coronary lesions needing physiological assessments.” The CAAS vFFR process reduces reliance on guiding catheters and invasive coronary instruments, which traditionally involve various risks and discomfort for patients.

Bas Kuppens, CEO of Pie Medical Imaging, emphasized, “FAST III marks a pivotal moment. The study validates angiographic-based physiology as equal to conventional pressure-wire-based methodologies, leading to enhanced benefits for both healthcare professionals and patients due to reduced dosages and shorter procedure durations.”

On a similar note, Doris Pommi, the head of cardiac care at Siemens Healthineers, underscored, “The results from the FAST III trial represent an important milestone for cardiovascular care in Europe and our collaboration with Pie Medical Imaging. The success highlights the effectiveness of combining scientific excellence with clinical experience and industrial innovation.”

Conclusion

The impact of this study cannot be overstated, as it promises safer, faster, and less uncomfortable coronary examinations with the potential for lower costs and broader access to physiological lesion assessments. As research continues, we can expect an evolving landscape in cardiovascular procedures, enhancing patient care and outcomes for those experiencing coronary artery issues.

For more information on CAAS vFFR and its ongoing innovations, visit the website of Pie Medical Imaging, which leads in advanced cardiovascular imaging solutions.